Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development.

Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved medicines, including Vpriv and Elaprase, which were granted accelerated approvals by the U.S. Food and Drug Administration (USFDA). Dr. Fahrner received his PhD in Biochemistry and Molecular Biology from UCLA.

Dr. Agajanov brings nearly 30 years of experience in clinical operations and clinical development, with a focus in oncology, immunology, and inflammation. She has served as SVP of Global Clinical Operations at Neurvati Neurosciences, VP of Clinical Operations at Ovid Therapeutics, Therapeutic Area Head of Oncology at Boehringer Ingelheim, and Associate Director of Immunology, Inflammation and Infectious Disease at Roche. Her leadership has been central to advancing multiple programs through late-stage clinical development.

“Both Dr. Fahrner and Dr. Agajanov have led the development of multiple products during their long careers and their expertise in accelerated approvals aligns with our strategy of designing robust but cost-efficient trials,” said Dr. Shiladitya Sengupta, Associate Professor of Medicine, Harvard Medical School, and Founder of Vyome. “We are delighted that both Dr. Agajanov and Dr. Fahrner decided to join the Vyome team, significantly bolstering our depth in developing next-generation therapies, as we embark on pivotal studies with our leading asset.”

Vyome is currently conducting a Ph2 study in malignant fungating wounds (MFW), a potential multi-billion dollar market opportunity. Topline results from this study are expected by October 2025.

“I am excited to join Vyome at this critical stage. The company has assembled a strong pipeline of scientifically and clinically validated programs that can create tremendous value in the near term,” said Dr. Fahrner. “The interim Phase 2 results in MFW are very encouraging, and this is an opportunity to develop a first-in-class therapy for patients with limited treatment options.”

“The addition of these leaders marks an important milestone in Vyome’s growth journey. We are now properly capitalized and have the right team in place to unlock the next milestones of value in our lead programs,” said Venkat Nelabhotla, CEO of Vyome. “Dr. Fahrner and Dr. Agajanov’s proven track records in drug development and clinical leadership add depth to our goal of creating shareholder value, especially given the promising interim Phase 2 data in malignant fungating wounds.”

About Vyome Holdings, Inc.

Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook”, and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements, include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, Vyome’s future operating results and liquidity and capital resources outlook. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome’s ability to raise capital to fund continuing operations; our ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions; and other factors relating to Vyome’s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Vyome’s assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release except as may be required under applicable securities law.